A Phase 3, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE 001)
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms RATIONALE001
- Sponsors Celgene Corporation
- 26 Oct 2019 This trial has been completed in Hungary and Portugal, according to European Clinical Trials Database record (Global End Date: 26 jun 2019).
- 26 Aug 2019 Status changed from recruiting to discontinued.
- 05 Jul 2019 This trial has been Discontinued at Finland